Anagnostopoulos, Gerasimos http://orcid.org/0000-0002-2042-8675
Motiño, Omar http://orcid.org/0000-0002-3858-0966
Li, Sijing
Carbonnier, Vincent
Chen, Hui
Sica, Valentina
Durand, Sylvère
Bourgin, Mélanie
Aprahamian, Fanny
Nirmalathasan, Nitharsshini
Donne, Romain http://orcid.org/0000-0002-8152-1283
Desdouets, Chantal http://orcid.org/0000-0002-1955-8915
Sola, Marcelo Simon
Kotta, Konstantina
Montégut, Léa
Lambertucci, Flavia
Surdez, Didier
Sandrine, Grossetête
Delattre, Olivier http://orcid.org/0000-0002-8730-2276
Maiuri, Maria Chiara http://orcid.org/0000-0001-9760-7674
Bravo-San Pedro, José Manuel
Martins, Isabelle http://orcid.org/0000-0003-0885-613X
Kroemer, Guido http://orcid.org/0000-0002-9334-4405
Funding for this research was provided by:
Fondation pour la Recherche Médicale
Ligue Contre le Cancer
Agence Nationale de la Recherche
Fondation Leducq
Institut National Du Cancer
Article History
Received: 7 March 2022
Revised: 24 March 2022
Accepted: 4 April 2022
First Online: 18 April 2022
Change Date: 3 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41419-022-04884-9
Competing interests
: GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sanofi, Sotio, Tollys, Vascage, and Vasculox/Tioma. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France and scientific co-founder of EverImmune, Samsara Therapeutics, Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis, and metabolic disorders. GK, JMB-SP, and OM are inventors of patents covering the therapeutic use of anti-ACBP/DBI antibodies. GK is the founder of Osasuna Therapeutics, which targets ACBP/DBI.